medRxiv
February 19, 2026
Amanda Gow, Emily Shih, Ryan Reid et al.
Abstract Background In 2020, Oregon became the first U.S. state to establish a regulated framework for adults to access psilocybin services using naturally-derived mushroom products. No studies have examined mental health outcomes among individuals receiving psilocybin in this context. Aims To evaluate changes in self-reported symptoms of depression, anxiety, and well-being 30-days...
medRxiv
February 17, 2026
Constantin Weberpals, A. Specht, Natasja Bonde Andersen et al.
Abstract Type 1 narcolepsy (NT1), a disorder caused by the loss of hypocretin/orexin transmission, is characterized by daytime sleepiness and symptoms where Rapid Eye Movement (REM) sleep, a state normally occurring from middle to late in the night, can intermingle with wakefulness. This results in cataplexy and sleep paralysis, episodes of muscle paralysis when awake, or in the generation of...
medRxiv
January 16, 2026
Kristian Larsen, Patrick M. Fisher, Drummond E. Mcculloch et al.
1 citation
Classical psychedelics have regained interest for their potential to treat psychiatric and neurological disorders, and explore neural mechanisms supporting perception, cognition, and mood. Acute psychedelic effects have been linked to increases in brain complexity and entropy, but it is unclear if these changes are specific to psychedelics or reflect more general psychoactive effects. Here, we...
medRxiv
January 16, 2026
Donald J. Noble, Charles L. Raison
Abstract Introduction The wellbeing of university undergraduates is a pressing area of concern, with one in five students reporting serious psychological distress. In previous semesters of a course on mental wellbeing, we asked undergraduates to engage with a standardized wellness program for the general population and provide feedback through weekly surveys and a final reflection paper. Based...
medRxiv
December 23, 2025
Chiranth Bhagavan, Olivia Carter, Glenn Nielsen et al.
1 citation
Abstract Background Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically relevant given the emerging interest in psychedelic-assisted physical therapy for disorders of motor function. This study’s primary objectives examined the feasibility and safety of administering movement tasks following low-to-moderate doses of...
medRxiv
November 20, 2025
Qing Wang, Lizhao Du, Jialing Sheng et al.
preprint
Whether and how meditation benefits severe psychosis over clinically meaningful timescales remains unclear. We embedded longitudinal neuroimaging in an eight-month, parallel group randomized clinical trial (ChiCTR1800014913) of male inpatients (n=64) with schizophrenia receiving daily clinician-guided meditation plus rehabilitation versus rehabilitation alone. Meditation improved the symptoms...
medRxiv
November 19, 2025
T. A. Stripp, N. Hvidt
preprint
Background: Near-death experiences (NDEs) are profound phenomena reported after life-threatening events such as cardiac arrest. The Near-Death Experience Content (NDE-C) scale was developed to improve psychometric assessment of NDE phenomenology, but no validated Danish version exists. Objective: To evaluate the psychometric properties of the Danish NDE-C scale among out-of-hospital cardiac...
medRxiv
November 17, 2025
Georgia Ioakimidis-Macdougall, John Gardner, Paul Liknaitzky
preprint
Abstract First-hand experience with psychedelics may help clinicians develop skills and knowledge needed to work with the profound changes to conscious awareness occasioned by psychedelics. However, the topic remains contentious and underexplored. In this world-first study, we investigated the utility of psilocybin experiential therapist training in a sample of 14 mental healthcare...
medRxiv
October 22, 2025
Matthew A Aldridge, Nanda Cara, Alan Simpson et al.
preprint
Abstract Second-generation mindfulness-based interventions (SG-MBIs) extend typical mindfulness-based interventions (MBIs) by grounding them in Buddhist epistemological and pedagogical frameworks and integrating additional Buddhist-derived practices. Systematic reviews show that MBIs can reduce burnout, distress, anxiety, depression and stress among university students—an issue of increasing...
medRxiv
September 25, 2025
B Gowthami, Ishita Mehta, Sneha Baiju et al.
1 citation
preprint
Abstract Introduction Treatment-resistant depression (TRD) affects up to one-third of patients with major depressive disorder, leading to poor outcomes and increased suicide risk. Esketamine nasal spray, a novel glutamatergic modulator, has emerged as an adjunctive option with rapid onset of action. However, the efficacy and safety of esketamine across randomized controlled trials (RCTs) remain...
medRxiv
August 28, 2025
Franziska Stadler, Johan Saelens, Ioline D. Henter et al.
preprint
This international online study (N=759) examined the acute, subacute, and long-term effects of psychedelic drug use on cognitive performance and mental health. Participants completed cognitive tasks assessing working memory, selective attention, and visual/spatial perception, as well as questionnaires assessing mental health outcomes and quality of life. Based on self-reported substance use,...
medRxiv
August 27, 2025
Md. Shahidul Islam, Md Sakib Ibne Salam, Md Nahid Hasan
1 citation
preprint
A bstract Contemporary psychedelic research highlights the value of user experience reports, yet their verbose, subjective nature poses challenges for clinical utility. This is the first study to pioneer unsupervised automatic text summarization of psychedelic user experience reports, a domain where no human-annotated reference summaries exist. To address this gap, we developed a custom scoring...
medRxiv
August 19, 2025
Jun Takezawa, Sinong Geng, Masahiro Fujino et al.
preprint
BACKGROUND: Mindfulness meditation has been reported to reduce stress and enhance well-being. However, its effects on heart rate variability (HRV)-a physiological marker of stress-remain underexplored. OBJECTIVE: This study aimed to examine how meditation practice is associated with subjective stress, HRV, and their interaction, using mobile health technologies. METHODS: This 3-week...
medRxiv
August 16, 2025
S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey et al.
preprint
Abstract Importance Depression is a major cause of disability worldwide, motivating substantial interest in psilocybin as a potential treatment. Objective To conduct a systematic review and meta-analysis of psilocybin’s impact on depressive symptoms and provide a living open data resource. Data Sources PubMed, Embase, Scopus, Web of Science, and PsycINFO retrieved by a systematic search up to...
medRxiv
August 7, 2025
Ben Deverett, Duan Li, Theresa R. Lii et al.
preprint
Structured Abstract Importance Ketamine has well known dissociative, analgesic, and antidepressant properties, but it is unknown whether the neurophysiologic effects that are associated with these properties can be modulated separately from one another. Given prior studies that link specific cortical oscillations with specific therapeutic effects, it is likely that modulating selective aspects...
medRxiv
July 29, 2025
Artemis Zavaliangos-Petropulu, Ginny Ghang, Toni Boltz et al.
preprint
Background: Treatment-resistant depression (TRD) affects 30-50% of patients with major depressive disorder (MDD). Electroconvulsive therapy (ECT) and sub-anesthetic ketamine treatment can relieve TRD, yet their antidepressant mechanisms remain unclear. Peripheral blood gene expression offers a non-invasive proxy to examine potential treatment-response biomarkers. Methods: We conducted a...
medRxiv
July 29, 2025
Yuwen He, Shan Lei, Wangli Si et al.
preprint
Abstract Background Somatic awareness is a fundamental practice for novice mindfulness practitioners. It has been proposed that mindfulness meditation training (MMT) enhances brain function through somatic awareness in both non-clinical and clinical populations. However, the neural signatures underlying this mechanism remain poorly understood. Methods In our study, we conducted mindfulness...
medRxiv
June 25, 2025
Devon Stoliker, Fosco Bernasconi, Olaf Blanke et al.
1 citation
preprint
Abstract Serotonergic psychedelics alter self-boundaries and can induce out-of-body experiences (OBEs)—the sense of being located outside one’s physical body. While OBEs also occur in clinical conditions and can be experimentally induced, their neural basis under psychedelics remains underexplored. In an open-label, baseline-controlled MRI study of 62 healthy adults administered psilocybin, we...
medRxiv
June 18, 2025
Drummond E-Wen Mcculloch, Kristian Larsen, Annette Johansen et al.
preprint
In this study, we provide the first study to integrate molecular and functional neuroimaging during psychedelic drug effects in humans. Using simultaneous PET-MRI technology, we describe multiple brain actions of lysergic acid diethylamide (LSD) in healthy volunteers. We quantify the occupancy of LSD at cerebral serotonin 2A receptors and show that LSD increases global cerebral blood flow and...
medRxiv
June 9, 2025
preprint
Efficacy and Moderators of Mindfulness-Based Cognitive Therapy (MBCT) in ‘Difficult to Treat’ Depression: Protocol for a Systematic Review and Individual Patient Data Meta-Analysis of Randomised Controlled Trials
medRxiv
May 29, 2025
Paul B. Fitzgerald, Sara Webb, Nigel Christopher Denning et al.
2 citations
preprint
Abstract Objective Despite many decades of experimental studies and clinical trials involving a variety of psychedelic agents, we still lack a comprehensive understanding of the effects of these substances on psychological experiences. As such, we designed and conducted a study to comprehensively characterise the effects of both psilocybin and 3,4-Methylenedioxymethamphetamine (MDMA) on a range...
medRxiv
May 29, 2025
Michael Y. Wang, Neil W. Bailey, Paul B. Fitzgerald et al.
preprint
Abstract Objective The dynamic impact of chronic pain on attention can lead to impairments in overall cognitive functioning. Mindfulness is a practice often adopted for pain management that includes elements of attention training. It is thought to improve the experiential acceptance of pain, thus reducing pain-sensitivity and pain-related attentional biases. The aim of this study was to examine...
medRxiv
May 27, 2025
Nathan J Wellington, Ana Paula Bouças, Paul Schwenn et al.
1 citation
preprint
Abstract Background Ketamine has emerged as a rapid-acting therapeutic option for post-traumatic stress disorder (PTSD); however, its ability to sustain long-term therapeutic outcomes remains poorly understood. Identifying molecular biomarkers predictive of a sustained response to ketamine may enhance personalised treatment strategies. This study investigates the epigenetic and transcriptomic...
medRxiv
March 24, 2025
Shraboni Ghosal, Mengying Zhang, Angeliki Bogosian et al.
1 citation
preprint
Abstract Introduction Mindfulness can positively impact physical and mental health, but face-to-face programmes are limited by poor accessibility, availability, and cost. Virtual reality (VR) offers immersive audio-visual environments that could improve mindfulness practice. Aim To evaluate commercially available VR apps related to mindfulness. Methods App stores and relevant online platforms...
medRxiv
February 7, 2025
Jakub Vohryzek, Anne Maj van der Velden, Willem Kuyken et al.
1 citation
preprint
BACKGROUND: Depression is a prevalent and debilitating affective disorder characterised by the dominance and persistence of depressive rumination. Mindfulness-based cognitive therapy (MBCT) is an effective treatment for recurrent depression developed specifically to target rumination and recurrence risk by training metacognitive awareness and adaptive attention, emotion and self-regulation...